Catalent reports 97% of its electricity usage comes from renewable sources
Catalent, a provider of delivery technologies and development and manufacturing solutions for drugs, biologics, and cell and gene therapies, announced that 97% of its electricity usage is procured from renewable energy sources such as wind, solar, hydroelectric, and biomass. Read More
Bruker's Q2 earnings show recovery from COVID-19
Bruker's second-quarter earnings report illustrates recovery from the COVID-19 pandemic, with a 34% increase in revenue compared to the same period in 2020. Read More
Autolus, Moderna ink license agreement
Biopharmaceutical company Autolus Therapeutics has granted Moderna exclusive license to develop and market mRNA therapeutics that include Autolus' binding agents for four immuno-oncology targets. Read More
Ipsen, Exicure sign spherical nucleic acid therapy license agreement
Ipsen and Exicure have signed an agreement giving Ipsen an exclusive option to license spherical nucleic acids Exicure is developing for Huntington's disease and Angelman syndrome. Read More
T-Knife Therapeutics raises $110M
T-Knife Therapeutics has secured $110 million in funding that it plans to use to further develop its T-cell receptor engineered T-cell therapies. Read More
Bio-Rad touts sales increases for Q2
Bio-Rad Laboratories announced sales increases in its second-quarter financial results for 2021. Read More
Alnylam to work with PeptiDream on peptide delivery of siRNA
Alnylam Pharmaceuticals and PeptiDream have signed a license and collaboration agreement to develop peptide-small interfering RNA (siRNA) conjugates that deliver RNA interference therapeutics to tissues outside the liver. Read More
Sciex, Genedata to develop new enterprise MS software
Sciex and Genedata have formed a strategic partnership to develop new software solutions for biopharmaceutical mass spectrometry (MS) applications. Read More
Astellas, Minovia partner on mitochondrial cell therapies
Astellas Pharma and Minovia Therapeutics have signed a strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction. Read More
Ligand reports record financial numbers for Q2
Ligand Pharmaceuticals reported record numbers for the second quarter of 2021. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
